TLX News: Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidn - 19th Dec 2023, 8:44am

[annb0t]

MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational positron emission tomography (PET) imaging agent TLX250-CDx (Zircaix™,[1] 89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC). (PRNewsfoto/Telix Pharmaceuticals Limited)

Under the Br...

>>> Read more: Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer